SCHEMBL23219240

SCHEMBL23219240

CCOC(=O)Cc1ccccc1OCc1nn(C(C)C)c2ccc(-c3ccnc(CN)c3OC)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 4/20 0.46
DPP4 P27487 2/20 0.39
TBXAS1 P24557 1/20 0.37
ICMT O60725 8/20 0.36
PTK2 Q05397 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TSPO P30536 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
AHR P35869 1/20 0.31
KMT2A Q03164 1/20 0.31
PLG P00747 1/20 0.31
PLAU P00749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852825 1.00 CFD (0.46) CFDDPP4TBXAS1ICMTPTK2
SCHEMBL23219133 0.92 CFD (0.48) CFDDPP4TBXAS1ICMTKDM4E
SCHEMBL29853067 0.92 CFD (0.48) CFDDPP4TBXAS1ICMTKDM4E
SCHEMBL29592611 0.92 CFD (0.39) CFDICMTPLGPLAUF11
SCHEMBL23219134 0.92 CFD (0.39) CFDICMTPLGPLAUF11
SCHEMBL23218894 0.90 CFD (0.46) CFDDPP4TBXAS1ICMTKDM4E
SCHEMBL29852545 0.90 CFD (0.46) CFDDPP4TBXAS1ICMTKDM4E
SCHEMBL29340316 0.90 CFD (0.40) CFDDPP4TBXAS1ICMTPTK2
SCHEMBL23218813 0.89 CFD (0.39) CFDDPP4TBXAS1ICMTPTK2
SCHEMBL29852652 0.89 CFD (0.39) CFDDPP4TBXAS1ICMTPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 CFD 3529/4885DPP4 544/4885TBXAS1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.